Investors bought into the stock on the news that it will be added to the S&P SmallCap 600 at the start of trading on April 4. That means that funds tracking the index will need to buy the stock, and ...
Vir has a promising pipeline, and expects to report data this year on several phase 2 clinical trials. Vir's revenue rose by 133.4% last year. The Food and Drug Administration recently made a decision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results